Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Krawczyk, Natalia ^a   Meier Stiegen, Franziska ^a   Banys, Malgorzata ^a   Neubauer, Hans ^a   Ruckhaeberle, Eugen ^a   Fehm, Tanja ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADLH1 PROTEIN; ANTINEOPLASTIC AGENT; CATUMAXOMAB; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; EVEROLIMUS; EXEMESTANE; HERMES ANTIGEN; MUCIN 1; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NERVE CELL ADHESION MOLECULE; NOTCH RECEPTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VISMODEGIB; WNT PROTEIN;

BONE MARROW; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL ADHESION; CELL HOMING; CELL PROLIFERATION; CIRCULATING TUMOR CELL; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; IMMUNOFLUORESCENCE; METASTASIS; NONHUMAN; PHENOTYPE; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CELL DISSEMINATION; BREAST TUMOR; CELL CULTURE; CELL DIFFERENTIATION; METABOLISM; PATHOLOGY; TUMOR EMBOLISM;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901814702     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/415721     Document Type: Review

References (112)

1. Braun S., Vogl F. D., Naume B., Janni W., Osborne M. P., Coombes R. C., Schlimok G., Diel I. J., Gerber B., Gebauer G., Pierga J.-Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.-F., Kundt G., Strobl B., Fehm T., Wong G. Y. C., Bliss J., Vincent-Salomon A., Pantel K., A pooled analysis of bone marrow micrometastasis in breast cancer. The New England Journal of Medicine 2005 353 8 793 802 2-s2.0-23944466427 10.1056/NEJMoa050434 (Pubitemid 41215488)
2. Rack B., Schindlbeck C., Schneeweiss A., Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Proceedings of the 33rd Annual San Antonio Breast Cancer Symposium 2010 S6 S5
3. Janni W., Vogl F. D., Wiedswang G., Synnestvedt M., Fehm T., Jückstock J., Borgen E., Rack B., Braun S., Sommer H., Solomayer E., Pantel K., Nesland J., Friese K., Naume B., Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clinical Cancer Research 2011 17 9 2967 2976 2-s2.0-79955491864 10.1158/1078-0432.CCR-10-2515
4. Xenidis N., Ignatiadis M., Apostolaki S., Perraki M., Kalbakis K., Agelaki S., Stathopoulos E. N., Chlouverakis G., Lianidou E., Kakolyris S., Georgoulias V., Mavroudis D., Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. Journal of Clinical Oncology 2009 27 13 2177 2184 2-s2.0-65549086081 10.1200/JCO.2008.18.0497
5. Rack B. K., Schindlbeck C., Andergassen U., Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. Journal of Clinical Oncology abstract 1003, 2010 28 15s
6. Fidler I. J., Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′ -deoxyuridine. Journal of the National Cancer Institute 1970 45 4 773 782 2-s2.0-0014865396
7. Frisch S. M., Screaton R. A., Anoikis mechanisms. Current Opinion in Cell Biology 2001 13 5 555 562 2-s2.0-0035480032 10.1016/S0955-0674(00)00251-9 (Pubitemid 32817013)
8. Cameron M. D., Schmidt E. E., Kerkvliet N., Nadkarni K. V., Morris V. L., Groom A. C., Chambers A. F., MacDonald I. C., Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Research 2000 60 9 2541 2546 2-s2.0-0034193321 (Pubitemid 30262450)
9. Kienast Y., Von Baumgarten L., Fuhrmann M., Klinkert W. E. F., Goldbrunner R., Herms J., Winkler F., Real-time imaging reveals the single steps of brain metastasis formation. Nature Medicine 2010 16 1 116 122 2-s2.0-73849129203 10.1038/nm.2072
10. Sleeman J. P., Nazarenko I., Thiele W., Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer 2011 128 11 2511 2526 2-s2.0-79953301542 10.1002/ijc.26027
11. Méhes G., Witt A., Kubista E., Ambros P. F., Circulating breast cancer cells rre frequently apoptotic. American Journal of Pathology 2001 159 1 17 20 2-s2.0-0035404539 (Pubitemid 33704186)
12. Larson C. J., Moreno J. G., Pienta K. J., Gross S., Repollet M., O'Hara S. M., Russell T., Terstappen L. W. M. M., Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry Part A 2004 62 1 46 53 2-s2.0-8144220008 10.1002/cyto.a.20073 (Pubitemid 39473452)
13. Their J. P., Epithelial-mesenchymal transitions in tumor progression. Nature Reviews Cancer 2002 2 6 442 454 2-s2.0-0036595629 (Pubitemid 37328941)
14. Guarino M., Epithelial-mesenchymal transition and tumour invasion. International Journal of Biochemistry and Cell Biology 2007 39 12 2153 2160 2-s2.0-34748812509 10.1016/j.biocel.2007.07.011 (Pubitemid 47484287)
15. Mani S. A., Guo W., Liao M.-J., Eaton E. N., Ayyanan A., Zhou A. Y., Brooks M., Reinhard F., Zhang C. C., Shipitsin M., Campbell L. L., Polyak K., Brisken C., Yang J., Weinberg R. A., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008 133 4 704 715 2-s2.0-43049165453 10.1016/j.cell.2008.03.027 (Pubitemid 351636299)
16. Brabletz T., EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 2012 22 6 699 701
17. Kasimir-Bauer S., Hoffmann O., Wallwiener D., Kimmig R., Fehm T., Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Researchearch 2012 14 1, article R15 2-s2.0-84855987633 10.1186/bcr3099
18. Giordano A., Gao H., Anfossi S., Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular Cancer Therapeutics 2012 11 11 2526 2534 10.1158/1535-7163.MCT-12-0460
19. Barriere G., Riouallon A., Renaudie J., Tartary M., Michel P. R., Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 2012 12 114 2-s2.0-84858740414 10.1186/1471-2407-12-114
20. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S., Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Researchearch 2009 11 4, article R46 2-s2.0-75449106680 10.1186/bcr2333
21. Eisemann N., Waldmann A., Katalinic A., Epidemiology of breast cancer-current figures and trends. Geburtsh Frauenheilk 2013 73 2 130 135
22. Melcher C., Scholz C., Jäger B., Hagenbeck C., Rack B., Janni W., Breast cancer: state of the art and new findings. Geburtshilfe und Frauenheilkunde 2012 72 3 215 224 2-s2.0-84859375965 10.1055/s-0031-1298320
23. Klein C. A., Parallel progression of primary tumours and metastases. Nature Reviews Cancer 2009 9 4 302 312 2-s2.0-63049102497 10.1038/nrc2627
24. Cristofanilli M., Budd G. T., Ellis M. J., Stopeck A., Matera J., Miller M. C., Reuben J. M., Doyle G. V., Allard W. J., Terstappen L. W. M. M., Hayes D. F., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England Journal of Medicine 2004 351 8 781 791 2-s2.0-4143094988 10.1056/NEJMoa040766 (Pubitemid 39095313)
25. Rack B. K., Schindlbeck C., Andergassen U., Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. Journal of Clinical Oncology abstract 1003, 2010 28 15s
26. Kolberg H., Luftner D., Lux M. P., Breast cancer 2012-new aspects. Geburtshilfe und Frauenheilkunde 2012 72 7 602 615 10.1055/s-0032-1315131
27. Franken B., de Groot M. R., Mastboom W. J., Vermes I., van der Palen J., Tibbe A. G., Terstappen L. W., Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Research 2012 14 5 R133
28. Molloy T. J., Bosma A. J., Baumbusch L. O., Synnestvedt M., Borgen E., Russnes H. G., Schlichting E., van't Veer L. J., Naume B., The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Researchearch 2011 13 3, article R61 2-s2.0-79958295369 10.1186/bcr2898
29. Bidard F.-C., Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., Marty M., Pierga J.-Y., Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Annals of Oncology 2009 21 4 729 733 2-s2.0-77951707834 10.1093/annonc/mdp391
30. Pierga J.-Y., Bidard F.-C., Mathiot C., Brain E., Delaloge S., Giachetti S., De Cremoux P., Salmon R., Vincent-Salomon A., Marty M., Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research 2008 14 21 7004 7010 2-s2.0-57049162148 10.1158/1078-0432.CCR-08-0030
31. Benoy I. H., Elst H., Philips M., Wuyts H., Van Dam P., Scharpé S., Van Marck E., Vermeulen P. B., Dirix L. Y., Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. British Journal of Cancer 2006 94 5 672 680 2-s2.0-33644837133 10.1038/sj.bjc.6602985 (Pubitemid 43361898)
32. Nieto Y., Franklin W. A., Jones R. B., Berman S. I., Pellom J., Barón A. E., Shpall E. J., Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biology of Blood and Marrow Transplantation 2004 10 6 415 425 2-s2.0-2442595664 10.1016/j.bbmt.2004.02.004 (Pubitemid 38647290)
33. Stathopoulou A., Vlachonikolis I., Mavroudis D., Perraki M., Kouroussis C., Apostolaki S., Malamos N., Kakolyris S., Kotsakis A., Xenidis N., Reppa D., Georgoulias V., Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Journal of Clinical Oncology 2002 20 16 3404 3412 2-s2.0-0037102125 10.1200/JCO.2002.08.135
34. Pierga J.-Y., Petit T., Delozier T., Ferrero J.-M., Campone M., Gligorov J., Lerebours F., Roché H., Bachelot T., Charafe-Jauffret E., Pavlyuk M., Kraemer S., Bidard F.-C., Viens P., Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. The Lancet Oncology 2012 13 4 375 384 2-s2.0-84859158912 10.1016/S1470-2045(12)70049-9
35. Liotta L. A., Kleinerman J., Saidel G. M., Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Research 1974 34 5 997 1004 2-s2.0-0016218630
36. Mathiesen R. R., Borgen E., Renolen A., Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research 2012 14 4 R117
37. Bidard F. C., Peeters D. J., Fehm T., Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet Oncology 2014 10.1016/S1470-2045(14)70069-5
38. Paget S., The distribution of secondary growths in cancer of the breast. The Lancet 1889 133 3421 571 573 2-s2.0-50549121134
39. Butler T. P., Gullino P. M., Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research 1975 35 3 512 516 2-s2.0-0016607434
40. Fidler I. J., The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nature Reviews Cancer 2003 3 6 453 458 2-s2.0-0038481970 10.1038/nrc1098 (Pubitemid 37328849)
41. Fidler I. J., Poste G., The "seed and soil" hypothesis revisited. The Lancet Oncology 2008 9 8 808 2-s2.0-47849101658 10.1016/S1470-2045(08)70201-8 (Pubitemid 352038320)
42. Langley R. R., Fidler I. J., The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer 2011 128 11 2527 2535 2-s2.0-79953300698 10.1002/ijc.26031
43. Lianidou E. S., Mavroudis D., Georgoulias V., Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer 2013 108 12 2426 2432
44. Fehm T., Müller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Löhberg C. R., Solomayer E., Rack B., Riethdorf S., Klein C., Schindlbeck C., Brocker K., Kasimir-Bauer S., Wallwiener D., Pantel K., HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Researchearch and Treatment 2010 124 2 403 412 2-s2.0-78649327274 10.1007/s10549-010-1163-x
45. Krawczyk N., Banys M., Hartkopf A., Hagenbeck C., Melcher C., Fehm T., Circulating tumour cells in breast cancer. Ecancermedicalscience 2013 7 352 10.3332/ecancer.2013.352
46. Nieto M. A., Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. International Journal of Developmental Biology 2009 53 8-10 1541 1547 2-s2.0-73949146501 10.1387/ijdb.072410mn
47. Acloque H., Adams M. S., Fishwick K., Bronner-Fraser M., Nieto M. A., Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. Journal of Clinical Investigation 2009 119 6 1438 1449 2-s2.0-67650996280 10.1172/JCI38019
48. Nieto M. A., Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013 342 6159 10.1126/science.1234850
49. Iwano M., Plieth D., Danoff T. M., Xue C., Okada H., Neilson E. G., Evidence that fibroblasts derive from epithelium during tissue fibrosis. Journal of Clinical Investigation 2002 110 3 341 350 2-s2.0-0036322007 10.1172/JCI200215518 (Pubitemid 34847966)
50. Hugo H., Ackland M. L., Blick T., Lawrence M. G., Clements J. A., Williams E. D., Thompson E. W., Epithelial-mesenchymal and mesenchymal- epithelial transitions in carcinoma progression. Journal of Cellular Physiology 2007 213 2 374 383 2-s2.0-34848826864 10.1002/jcp.21223 (Pubitemid 47509716)
51. Yao D., Dai C., Peng S., Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Molecular Cancer Research 2011 9 12 1608 1620 2-s2.0-84055216938 10.1158/1541-7786.MCR-10- 0568
52. Chao Y. L., Shepard C. R., Wells A., Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Molecular Cancer 2010 9, article 179 2-s2.0-77954304397 10.1186/1476-4598-9-179
53. Imai T., Horiuchi A., Shiozawa T., Osada R., Kikuchi N., Ohira S., Oka K., Konishi I., Elevated expression of E-cadherin and α -, β -, and γ -catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Human Pathology 2004 35 12 1469 1476 2-s2.0-10944268101 10.1016/j.humpath.2004.09.014 (Pubitemid 40017986)
54. Thiery J. P., Acloque H., Huang R. Y. J., Nieto M. A., Epithelial-mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 2-s2.0-70450198396 10.1016/j.cell.2009.11.007
55. Sarrió D., Rodriguez-Pinilla S. M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J., Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 2008 68 4 989 997 2-s2.0-39449095723 10.1158/0008-5472.CAN-07-2017 (Pubitemid 351272216)
56. Dumont N., Wilson M. B., Crawford Y. G., Reynolds P. A., Sigaroudinia M., Tlsty T. D., Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America 2008 105 39 14867 14872 2-s2.0-54449085718 10.1073/pnas.0807146105
57. Ross A. A., Cooper B. W., Lazarus H. M., Mackay W., Moss T. J., Ciobanu N., Tallman M. S., Kennedy M. J., Davidson N. E., Sweet D., Winter C., Akard L., Jansen J., Copelan E., Meagher R. C., Herzig R. H., Klumpp T. R., Kahn D. G., Warner N. E., Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993 82 9 2605 2610 2-s2.0-0027374446 (Pubitemid 23318065)
58. Fehm T., Sagalowsky A., Clifford E., Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clinical Cancer Research 2002 8 7 2073 2084 2-s2.0-0037343074 (Pubitemid 34753576)
59. Theodoropoulos P. A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., Georgoulias V., Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Letters 2010 288 1 99 106 2-s2.0-73649125337 10.1016/j.canlet.2009.06.027
60. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E. F., Wallwiener D., Kimmig R., Kasimir-Bauer S., Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Researchearch 2009 11 4, article R59 2-s2.0-77449088191 10.1186/bcr2349
61. Cristofanilli C., Hayes D. F., Budd G. T., Ellis M. J., Stopeck A., Reuben J. M., Doyle G. V., Matera J., Allard W. J., Miller M. C., Fritsche H. A., Hortobagyi G. N., Terstappen L. W., Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology 2005 23 7 1420 1430
62. Lowes L. E., Hedley B. D., Keeney M., Allan A. L., User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch(R) system. Cytometry Part A 2012 81 11 983 995 10.1002/cyto.a.22158
63. Flores L. M., Kindelberger D. W., Ligon A. H., Capelletti M., Fiorentino M., Loda M., Cibas E. S., Jänne P. A., Krop I. E., Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. British Journal of Cancer 2010 102 10 1495 1502 2-s2.0-77952120469 10.1038/sj.bjc.6605676
64. Sieuwerts A. M., Kraan J., Bolt-De Vries J., Van Der Spoel P., Mostert B., Martens J. W. M., Gratama J.-W., Sleijfer S., Foekens J. A., Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Researchearch and Treatment 2009 118 3 455 468 2-s2.0-70449598075 10.1007/s10549-008-0290-0
65. Demel U., Tilz G. P., Foeldes-Papp Z., Gutierrez B., Albert W. H., Böcher O., Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. Journal of Experimental and Clinical Cancer Research 2004 23 3 465 468 2-s2.0-8544224277 (Pubitemid 39490631)
66. Lankiewicz S., Rivero B. G., Bócher O., Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Molecular Biotechnology 2006 34 1 15 27 2-s2.0-33748352340 10.1385/MB:34:1:15 (Pubitemid 44337216)
67. Nagrath S., Sequist L. V., Maheswaran S., Bell D. W., Irimia D., Ulkus L., Smith M. R., Kwak E. L., Digumarthy S., Muzikansky A., Ryan P., Balis U. J., Tompkins R. G., Haber D. A., Toner M., Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007 450 7173 1235 1239 2-s2.0-37549002543 10.1038/nature06385
68. Stott S. L., Hsu C.-H., Tsukrov D. I., Yu M., Miyamoto D. T., Waltman B. A., Michael Rothenberg S., Shah A. M., Smas M. E., Korir G. K., Floyd F. P. Jr., Gilman A. J., Lord J. B., Winokur D., Springer S., Irimia D., Nagrath S., Sequist L. V., Lee R. J., Isselbacher K. J., Maheswaran S., Haber D. A., Toner M., Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America 2010 107 43 18392 18397 2-s2.0-78649872067 10.1073/pnas.1012539107
69. Yu M., Bardia A., Wittner B. S., Stott S. L., Smas M. E., Ting D. T., Isakoff S. J., Ciciliano J. C., Wells M. N., Shah A. M., Concannon K. F., Donaldson M. C., Sequist L. V., Brachtel E., Sgroi D., Baselga J., Ramaswamy S., Toner M., Haber D. A., Maheswaran S., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013 339 6119 580 584 10.1126/science.1228522
70. Farace F., Massard C., Vimond N., Drusch F., Jacques N., Billiot F., Laplanche A., Chauchereau A., Lacroix L., Planchard D., Le Moulec S., André F., Fizazi K., Soria J. C., Vielh P., A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer 2011 105 6 847 853 2-s2.0-80052511419 10.1038/bjc.2011.294
71. Fasching P., Gumbrecht W., Fehm T. N., 4EVER: assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2-negative, estrogen receptor-positive, advanced breast cancer patients. Journal of Clinical Oncology 2013 31 15 591
72. Pantel K., C K., Alix-panabieres, detection methods of circulating tumor cells. J Thorac Dis 2012 4 5 446 447
73. Fehm T., Braun S., Muller V., Janni W., Gebauer G., Marth C., Schindlbeck C., Wallwiener D., Borgen E., Naume B., Pantel K., Solomayer E., A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006 107 5 885 892 2-s2.0-33747893501 10.1002/cncr.22076 (Pubitemid 44291136)
74. Mego M., Mani S. A., Lee B.-N., Li C., Evans K. W., Cohen E. N., Gao H., Jackson S. A., Giordano A., Hortobagyi G. N., Cristofanilli M., Lucci A., Reuben J. M., Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. International Journal of Cancer 2012 130 4 808 816 2-s2.0-83955165959 10.1002/ijc.26037
75. Armstrong A. J., Marengo M. S., Oltean S., Kemeny G., Bitting R. L., Turnbull J. D., Herold C. I., Marcom P. K., George D. J., Garcia-Blanco M. A., Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 2011 9 8 997 1007 2-s2.0-80051988763 10.1158/1541-7786.MCR-10-0490
76. Kallergi G., Papadaki M. A., Politaki E., Mavroudis D., Georgoulias V., Agelaki S., Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Researchearch 2011 13 3, article R59 2-s2.0-84860397754 10.1186/bcr2896
77. Mego M., Gao H., Lee B. N., Cohen E. N., Tin S., Giordano A., Wu Q., Liu P., Nieto Y., Champlin R. E., Hortobagyi G. N., Cristofanilli M., Ueno N. T., Reuben J. M., Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose chemotherapy with autologous hematopoietic stem cell transplantation. Journal of Cancer 2012 3 369 380
78. Raimondi C., Gradilone A., Naso G., Vincenzi B., Petracca A., Nicolazzo C., Palazzo A., Saltarelli R., Spremberg F., Cortesi E., Gazzaniga P., Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Researchearch and Treatment 2011 130 2 449 455 2-s2.0-82955187028 10.1007/s10549-011-1373-x
79. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R. H., Cote R. J., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research 2006 12 19 5615 5621 2-s2.0-33750306612 10.1158/1078-0432.CCR-06-0169 (Pubitemid 44629587)
80. Reuben J. M., Lee B.-N., Gao H., Cohen E. N., Mego M., Giordano A., Wang X., Lodhi A., Krishnamurthy S., Hortobagyi G. N., Cristofanilli M., Lucci A., Woodward W. A., Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44 + CD24 lo cancer stem cell phenotype. European Journal of Cancer 2011 47 10 1527 1536 2-s2.0-79958852461 10.1016/j.ejca.2011.01.011
81. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F., Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 3983 3988 2-s2.0-0037388204 10.1073/pnas.0530291100 (Pubitemid 36418143)
82. Reya T., Morrison S. J., Clarke M. F., Weissman I. L., Stem cells, cancer, and cancer stem cells. Nature 2001 414 6859 105 111 2-s2.0-0035499267 10.1038/35102167 (Pubitemid 33041634)
83. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P. G., Di Fiore P. P., Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010 140 1 62 73 2-s2.0-73149110562 10.1016/j.cell.2009.12.007
84. Abraham B. K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H., Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research 2005 11 3 1154 1159 2-s2.0-12944288172 (Pubitemid 40175765)
85. Morel A.-P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A., Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008 3 8 2-s2.0-51449085561 10.1371/journal.pone.0002888 e2888
86. Monteiro J., Fodde R., Cancer stemness and metastasis: therapeutic consequences and perspectives. European Journal of Cancer 2010 46 7 1198 1203 2-s2.0-77950591041 10.1016/j.ejca.2010.02.030
87. Bidard F. C., Fehm T., Ignatiadis M., Smerage J. B., Alix- Panabières C., Janni W., Messina C., Paoletti C., Müller V., Hayes D. F., Piccart M., Pierga J. Y., Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer and Metastasis Reviews 2013 32 1-2 179 188
88. Banys M., Müller V., Melcher C., Aktas B., Kasimir-Bauer S., Hagenbeck C., Hartkopf A., Fehm T., Circulating tumor cells in breast cancer. Clinica Chimica Acta 2013 423 39 45 10.1016/j.cca.2013.03.029
89. Gorges T. M., Tinhofer I., Drosch M., Röse L., Zollner T. M., Krahn T., von Ahsen O., Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012 12 178 10.1186/1471-2407-12-178
90. Pietzner K., Jäger M., Schoberth A., Oskay-Özcelik G., Kuhberg M., Lindhofer H., Sehouli J., First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Medical Oncology 2012 29 2 1391 1396 2-s2.0-79955494475 10.1007/s12032-011-9961-5
91. Baumann K., Pfisterer J., Wimberger P., Burchardi N., Kurzeder C., Du Bois A., Loibl S., Sehouli J., Huober J., Schmalfeldt B., Vergote I., Lück H. J., Wagner U., Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology 2011 123 1 27 32 2-s2.0-80052593787 10.1016/j.ygyno.2011.06.004
92. Luftner D., Lux M. P., Maass N., Schutz F., Schwidde I., Fasching P. A., Fehm T., Janni W., Kummel S., Kolberg H. C., Advances in breast cancer-looking back over the year. Geburtsh Frauenheilk 2012 72 12 1117 1129
93. Zhu Y., Zhang X., Liu Y., Zhang S., Liu J., Ma Y., Zhang J., Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumor Biology 2012 33 5 1349 1362 2-s2.0-84859375454 10.1007/s13277-012-0383-6
94. Zhang X., Zhang S., Liu Y., Liu J., Ma Y., Zhu Y., Zhang J., Effects of the combination of RAD001 and docetaxel on breast cancer stem cells. European Journal of Cancer 2012 48 10 1581 1592 2-s2.0-84857958229 10.1016/j.ejca.2012. 02.053
95. Liu H., Zhang H. W., Sun X. F., Guo X. H., He Y. N., Cui S. D., Fan Q. X., Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties. Chinese Medical Journal 2013 126 16 3030 3034
96. Bachelot T., Bourgier C., Cropet C., Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology 2012 30 22 2718 2724 10.1200/JCO.2011.39.0708
97. Baselga J., Campone M., Piccart M., Burris H. A. III, Rugo H. S., Sahmoud T., Noguchi S., Gnant M., Pritchard K. I., Lebrun F., Beck J. T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G. N., Everolimus in postmenopausal hormone-receptor- positive advanced breast cancer. The New England Journal of Medicine 2012 366 6 520 529 2-s2.0-84856777655 10.1056/NEJMoa1109653
98. Cui W., Wang L.-H., Wen Y.-Y., Song M., Li B.-L., Chen X.-L., Xu M., An S.-X., Zhao J., Lu Y.-Y., Mi X.-Y., Wang E.-H., Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Science 2010 101 4 927 933 2-s2.0-77956051646 10.1111/j.1349-7006.2010.01495.x
99. Souzaki M., Kubo M., Kai M., Kameda C., Tanaka H., Taguchi T., Tanaka M., Onishi H., Katano M., Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Science 2011 102 2 373 381 2-s2.0-79952088432 10.1111/j.1349-7006.2010.01779.x
100. Al-Hussaini H., Subramanyam D., Reedijk M., Sridhar S. S., Notch signaling pathway as a therapeutic target in breast cancer. Molecular Cancer Therapeutics 2011 10 1 9 15 2-s2.0-78751557260 10.1158/1535-7163.MCT-10-0677
101. Reedijk M., Notch signaling and breast cancer. Advances in Experimental Medicine and Biology 2012 727 241 257 2-s2.0-84859482094 10.1007/978-1-4614- 0899-4-18
102. Rasul S., Balasubramanian R., Filipovi A., Slade M. J., Yagüe E., Coombes R. C., Inhibition of γ -secretase induces G2M arrest and triggers apoptosis in breast cancer cells. British Journal of Cancer 2009 100 12 1879 1888 2-s2.0-67149138004 10.1038/sj.bjc.6605034
103. Kondratyev M., Kreso A., Hallett R. M., Girgis-Gabardo A., Barcelon M. E., Ilieva D., Ware C., Majumder P. K., Hassell J. A., Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 2012 31 1 93 103 2-s2.0-84855344803 10.1038/onc.2011.212
104. Krop I., Demuth T., Guthrie T., Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology 2012 30 19 2307 2313 10.1200/JCO.2011.39.1540
105. UoM, C., Phase I/II Study of MK-0752 Followed By Docetaxel in Advanced Metastatic Breast Cancer. Clinical Trials.Gov [Internet] 2000 Bethesda, Md, USA National Library of Medicine (US)
106. BAKC, I., GDC-0449 and R04929097 in Treating Women With Advanced Breast Cancer. Clinical Trialsgov 2000 Bethesda, Md, USA National Library of Medicine
107. Ramaswamy B., Lu Y., Teng K. Y., Nuovo G., Li X., Shapiro C. L., Majumder S., Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Research 2012 72 19 5048 5059 10.1158/0008-5472.CAN-12-1248
108. Hallett R. M., Kondratyev M. K., Giacomelli A. O., Nixon A. M. L., Girgis-Gabardo A., Ilieva D., Hassell J. A., Small molecule antagonists of the Wnt/Beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS ONE 2012 7 3 2-s2.0-84859032134 10.1371/journal.pone.0033976 e33976
109. Bhat-Nakshatri P., Goswami C. P., Badve S., Sledge Jr G. W., Nakshatri H., Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Scientific Reports 2013 3 2530 10.1038/srep02530
110. Bryan M., Pulte E. D., Toomey K. C., Pliner L., Pavlick A. C., Saunders T., Wieder R., A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Investigational New Drugs 2011 29 6 1482 1487 2-s2.0-84856050828
111. Gupta P. B., Onder T. T., Jiang G., Tao K., Kuperwasser C., Weinberg R. A., Lander E. S., Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009 138 4 645 659 2-s2.0-68749099671 10.1016/j.cell.2009.06.034
112. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q., The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012 33 2 679 691 2-s2.0-80055112766 10.1016/j.biomaterials.2011. 09.072